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Abstract
Objective: Aortic valve replacement is a routine procedure
with acceptable risk, but in some cases, such risk can justify
contraindication. Minimally invasive transcatheter aortic
valve implantation has emerged as an alternative, with lower
morbidity and mortality. The aim of this study was clinical,
safety and efficacy assessment.
Methods: Thirty-three high risk patients underwent
transcatheter balloon expandable aortic valve implantation.
Mean Logistic EuroScore risk was 39.30% and STS score
30.28%. Eight patients presented with dysfunctional
bioprosthesis, remaining ones presented calcified aortic
stenosis. Procedures were performed in a hybrid OR under
fluoroscopic and echocardiography guidance. Using a left
minithoracotomy the prosthesis were implanted trough the
ventricular apex under rapid ventricular pacing or
hemorrhagic shock. Echocardiographic and angiographic
controls were performed.
Results: Implant was feasible in 30 cases. Three
conversions occured. There was only one case of operative
death. Median transvalvular aortic gradient reduced from
43.58 mmHg to 10.54 mmHg. Left ventricular function
improved in the first 7 postoperative days. Paravalvular
aortic regurgitation was mild and present in 30.30%. One
case presented major vascular complication and another one
permanent pacemaker implant. One major stroke case
occurred. Overall 30-day mortality was 18.18%.
Conclusion: The transapical implantation of catheter-
mounted bioprosthesis is a safe procedure with acceptable
midterm results. Long term follow-up with increased sample
power is mandatory in order to access hemodynamic, life
quality and survival.
Descriptors: Aortic valve. Cardiopulmonary bypass. Heart
catheterization.
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INTRODUCTION
The degenerative calcification of the aortic valve is
considered the most common cause of aortic stenosis in
developed countries, the most frequent indication for aortic
valve replacement [1-5]. Standard treatment involves
replacing of the valve by a prosthetic device (biological or
mechanical) with operative mortality around 4% [6.7].
Despite these results some patients present
morbimortality very high. Age advanced coronary grafts
pervious, extensive thoracic irradiation, porcelain aortas,
previous operations, biological fragility and neediness
symptomatology well documented are factors that increase
surgical risk. The conjunction these factors can determine
contraindication procedure within 30% cases despite
symptomatology or presence of structural cardiac
commitment [8.9].
Recently, several groups have proposed alternative
therapies aiming to reduce morbimortality associated with
conventional intervention. Aortic valvuloplasty balloon was
one these first interventions. Unfortunately after short
improves, patients return showing symptoms and mortality
comparable with pharmacological treatment [10]. In recent years
implantation of one bioprosthesis aortic through catheters
has been proposed with same goal, but more consistently
[11.12]. Improvement of these devices, like reducing caliber
introducers and structural improvements has provided
increment significant result [13]. The Partner Trial (Placement
of Aortic Transcatheter) randomized study comparing
transcatheter clinical therapy demonstrated superiority of last
both regarding mortality as quality life [14].
Despite encouraging results exists large discrepancy
among results of different groups especially due
heterogeneity of patients assessed with different risk
scores and selection criteria [15.16].
Two devices are available commercially for transcatheter
implantation in the aortic valve: Edwards Sapien
(expandable balloon) (Edwards Lifesciences, CA, USA) and
CoreValve (self expandable) (Medtronic Corporation MN,
USA) both with distinct structural characteristics. In our
environment it was developed one expandable balloon
prosthesis with encouraging initial results [17.18].
Assessment of clinical outcomes, safety and efficacy
of the procedure performed with this new prosthesis are
the aim of this study.
METHODS
Patient Selection
Between June 2008 and January 2011, 33 patients
underwent transcatheter aortic valve implantation, after
agreeing with written informed consent and approval by
the Ethics Committee (CEP 1116/08).
Patients were selected by one multidisciplinary group.
Patient selection involved, beyond multidisciplinary query
and criteria inclusion and exclusion, consideration of
aspects such as high surgical risk, expectation, life quality
and assessment of biological fragility. Biological Frailty was
evaluated based analyzing multiple factors like mobility,
strength, capacity of perform activities of daily life,
nutritional status and presence of cognitive deficits. The
EuroSCORE and STS score were used in order to provide
Resumo
Objetivo: A troca valvar aórtica é procedimento rotineiro
com risco aceitável. Em alguns casos, a mortalidade é
elevada, contraindicando o procedimento. O implante
minimamente invasivo transcateter de valva aórtica parece
ser alternativa, reduzindo a morbimortalidade. A avaliação
dos resultados clínicos, segurança e eficácia do procedimento
são o objetivo desse estudo.
Métodos: Uma prótese transcateter, balão expansível foi
utilizada em 33 casos de alto risco. EuroScore médio foi de
39,30% e STS score de 30,28%. Oito pacientes apresentavam
disfunção de bioprótese e o restante, estenose aórtica
calcificada. Os procedimentos foram realizados em ambiente
cirúrgico híbrido, sob controle ecocardiográfico e
fluoroscópico. Através de minitoracotomia esquerda, as
próteses foram implantadas pelo ápice ventricular, sob
estimulação de alta frequência ou choque hemorrágico.
Foram realizados controles clínicos e ecocardiográficos.
Resultados: A correta liberação da prótese foi possível em
30 casos. Três conversões ocorreram. A mortalidade
operatória foi de um caso e a mortalidade em 30 dias, 18,18%.
O gradiente médio reduziu de 43,58 para 10,54 mmHg. A
fração de ejeção apresentou aumento significativo após o 7º
pós-operatório. Insuficiência aórtica residual esteve presente
em 30,30% dos pacientes. Ocorreu uma complicação vascular
periférica e um caso de bloqueio atrioventricular total. Um
paciente apresentou acidente vascular cerebral. A
mortalidade em 30 dias foi de 18,18%.
Conclusão: O implante transapical de valva aórtica
transcateter é procedimento seguro e com resultados de médio
prazo satisfatórios. São necessários estudos de longo prazo
com maior poder amostral no intuito de determinar resultado
hemodinâmico, qualidade de vida e sobrevida em longo prazo.
Descritores: Valva aórtica. Ponte cardiopulmonar.
Cateterismo cardíaco.
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quantitative analysis of the individual risk involved in
procedure.
Patients underwent clinical, laboratory, echocardiogram,
cineangiocoronariography (when clinical condition
permitting) and Doppler ultrasonography examinations of
the iliac  femoral and carotid system.
Inclusion and exclusion criteria are referred in another
publication [18].
Demographic and comorbidities of the patients are
listed in Table 1.
Table 1. Demographic characteristics and comorbidities.
Characteristics
Age in years (mean/range)
Female (n/%)
Systemic Arterial Hypertension (n/%)
Diabetes (n/%)
Dyslipidemia (n/%)
Glomerular filtration rate < 50 mL/min (n/%)
Renal dialysis
Restrictive/obstructive lung disease (n/%)
Pulmonary arterial hypertension (n/%)
Operated in the presence of hospitalization for
decompensation (n/%)
Atrial fibrillation (n/%)
Functional type – NYHA (n/%)
II
III
IV
Comorbidities
Coronary artery disease (n/%)
Previous coronary angioplasty (n/%)
Prior cardiovascular surgery (n/%)
Peripheral arterial disease (n/%)
Previous stroke (n/%)
Cancer (n/%)
Porcelain aorta (n/%)
Chagas (n/%)
Sickle cell anemia (n/%)
Biological vulnerability (Frailty) (n/%)
“Valve-in-valve” (n/%)
Logistic EuroSCORE (%) (mean/range)
STS score (%) (mean/range)
Peak aortic gradient (mean ± standard deviation)
Mean aortic gradient (mean ± standard deviation)
Left ventricular ejection fraction (mean ±
standard deviation)
n=33
75.51/34-88
17/51.51
31/93.93
7/21.21
20/60.60
26/78.78
2/6.06
11/33.33
9/27.27
13/39.39
9/27.27
4/12.12
11/33.33
18/54.54
18/54.54
8/24.24
16/48.48
17/51.51
2/6.06
1/3.03
6/18.18
1/3.03
1/3.03
15/45.45
8/24.24
39.30/5.85-90.3
30.28/4.8-62.9
75.41±22.64
43.58±14.67
49.23±13.50
NYHA – New York Heart Association
Fig. 1 - Aortography control, demonstrating the correct positioning
of the prosthesis in relation to the valve annulus, coronary ostia
patency and absence of aortic insufficiency
Device and Procedure
The implant of transapical aortic valve was performed
according technique described previously [18]. Was used
in all cases expandable transcatheter balloon bioprosthesis
(Braile Biomédica, São José do Rio Preto, Brazil), in sizes 20
to 26 mm in diameter, as the aortic valve or the inner diameter
of the bioprosthesis dysfunction, considering one on the
size 10% (Figure 1).
Intraoperative transesophageal echocardiographic
controls were performed after valve implantation and
hemodynamic stabilization in order checking correct
prosthetic valvar functioning as well as its hemodynamics.
In cases where it was verified perivalvar aortic insufficiency
it was performed a new ballooning prosthesis with induced-
hypotension. Aortography control was only performed in
cases of doubt on echocardiographic valvar functioning
or suspected interference with coronary ostia.
After the procedure, all patients were maintained on
protocol of double antiaggregation using acetylsalicylic
acid and clopidogrel.
Follow-up and Outcomes
Procedural success was defined as a correct implant,
with satisfactory hemodynamic profile and absence of
significant valvar and perivalvular leaks and absence of
major immediate complications.
Patients were followed serially in the postoperative
follow-up: 1 day, 7 days, 30 days, 6 months, 12 months, 18
months and 24 months. Clinical and echocardiographic
assessments were performed.
The outcomes evaluated were all-cause mortality (30
days, and overall post-discharge), major cardiovascular
events, rehospitalization for prosthetic valve dysfunction
or clinical deterioration, functional class, stroke, vascular
complications, renal failure and bleeding.
Stroke and AMI were defined according
recommendations of the Valve Academic Research
Consortium [19].
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Statistical analysis
Statistical analysis was performed using SPSS version
11. The confidence level 0.05 was used as significant.
Comparison between averages used testing of Friedman
after verification of normal distribution of the values. Mean
and standard error were used to express analyzes, unless
specified otherwise. Kaplan-Meyer curve was used for
analyzes of adequate survival outcomes.
RESULTS
Procedure
All cases were performed in the institution in hybrid
surgical room. The valvar implant was successfully possible
in 30 cases. Three immediate conversions occurred: two by
migration of the prosthesis and one by hemodynamic
deterioration after implantation.
Mean time of implantation was 183.21 ± 78.19 minutes.
Mean time of fluoroscopy was 13.23 ± 6.01 minutes.
Averaged quantity of contrast used was 27.87 ± 39.98 mL,
while in second half of the casuistry it was 4.70 ± 13.28 mL.
Operative mortality was of one case. There was no need of
implant over one valve in the same patient. Major vascular
complication occurred in one case (rupture of iliac vein
during femoral cannulation requiring minilaparotomy). Two
cases of definitive pacemaker occurred: one by atrial
fibrillation of low ventricular response at day 15 of
postoperative still in the hospital phase and one due to
total atrioventricular block after discharged on the 45th
postoperative day.
Table 2. Operative variables.
Variable
Procedural success (n/%)
Conversion to conventional replacement (n/%)
Defibrillation (n/%)
Intallation of CPB (excluding conversions)
Contrast (mL) (mean)
Fluoroscopy time (min) (mean ± standard
deviation)
Procedure time (min) (mean ± standard
deviation)
n=33
30/90.91
2/6.06
2/6.06
1/3.03
27.87
13.23±6.01
182.66±75.52
Fig. 2 - Kaplan-Meier curve for all-cause mortality and mortality after hospital discharge
The following sizes of the devices were : 3 of 20 mm, 8 of
22 mm, 11 of 24 mm and 11 of 26 mm. Cases of valve-in-valve
used prostheses: 2 of 20 mm, 4 of 22 mm and 2 of 24 mm.
The follow ran-up ranged from 1 to 21 months.
Operative Variables are listed in Table 2.
Mortality and rehospitalization
Mortality in 30 days was 18.18%. There were 12 hospital
deaths (before discharge) these were due to following
complications: bronchopneumonia (four cases: 32, 53, 112
and 418 days) tracheoesophageal fistula (one case: 392
days) sepsis with infection of bloodstream (five cases: 5 16
17, 21:31 days), AMI (one case: 54 days) and stroke (one
case: 24 days). During post hospital discharge follow-up
occurred two deaths: one case due to Influenza H1N1 (90
Gaia DF, et al. - Transcatheter aortic valve implantation: results of
the current development and implantation of a new Brazilian
prosthesis
Rev Bras Cir Cardiovasc 2011;26(3):338-47
342
days) and another by cardiogenic shock with
normofunctioning prosthesis (52 days).
Survival at 6, 12 and 18 months calculated by the Kaplan-
Meyer was respectively of 61.5%, 61.5% and 53.8%.
Survival in patients discharged derived from Kaplan-Meyer
curve at 6, 12 and 18 months was 90.7% (Figure 2).
Rate of rehospitalization was 15.15% while after sixth
months occurred only one rehospitalization. Their causes
were 1. Lobar pneumonia; 2. Left hemothorax probably
secondary to apical ventricular bleeding requiring thoracic
drainage; 3. Left pleural effusion requiring thoracentesis;
4. Aortic insufficiency with a new episode of valvar
ballooning 5. Cardiogenic shock; 6. Total atrioventricular
block, requiring definitive pacemaker.
Complications
Other complications are related in Table 2.
Evolution of functional class
Functional class presented significant improvement
comparing preoperatively with 1, 6 and 12 months (P
<0.0001). Comparison between 1, 6 and 12 months did not
demonstrate statistically significant difference (Figure 3).
Echocardiographic evaluation
The hemodynamic results assessed by
echocardiography was satisfactory, with significant
reduction of peak gradient of 75.41 ± 22.64 21.32 ± 12.42
mmHg for the first postoperative day (P <0.001). Evolution
demonstrated that this reduction gradient was maintained
in subsequent exams without statistically significant
between gradient obtained after implantation in the
immediate postoperative (Figure 4). The gradient also
demonstrated significant reduction 43.58 ± 14.67 mmHg to
10.54 ± 6.90 mmHg in 1st postoperative day (P <0.001).
Evolution also demonstrated maintenance of this reduction
(Figure 4).
Fig. 4 - A. Peak aortic transvalvular gradients in the pre-,1st, 7th, 30th, 180th, 360th postoperatively. B. Mean aortic transvalvular gradients
pre-, 1st, 7th, 30th, 180th, 360th postoperatively
A B
Preoperative versus 1st postoperative – p<0.001
1st postoperative versus the subsequent days p>0.05
Preoperative versus 1st postoperative – p<0.001
1st postoperative versus the subsequent days p>0.05
Fig. 3 - Evolution of NYHA functional class
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Periprothetic aortic insufficiency in the immediate
postoperative occurred in 10 (30.30%) cases being
insufficiency 1 + in 15.15%, 2 + in 12.12% and 3 + 3.03%.
Distribution and aortic regurgitation severity were
maintained over the observation period and trending to
decrease. In patients undergoing valve-in-valve
implantation peri or transprosthetic aortic insufficiency did
not occurr. One patient required reintervention, with a new
episode of balloon inflation of the prosthesis on the 4th
month of postoperative due to severe paraprosthetic
regurgitation and resolution after the procedure, with no
associated mortality.
Ventricular function measured by left ventricular ejection
fraction by the method of Simpson presented improvement
statistically significant 49.23 ± 13.50 for 55.93 ± 11.53 on the
seventh days postoperative (P <0.01), sustained during
the follow-up (Figure 5).
Intraoperative Variables are listed in Table 2.
DISCUSSION
Aortic valve replacement is the procedure of choice for
patients with aortic valve stenosis or prosthetic
dysfunction. In the majority of the population, the
intervention has low risk and is able to promote functional
improvement and increase the survival rate when compared
to medical treatment [6]. Even in aged-advanced patients
they may present acceptable risk in centers of great
experience [20].
Despite these evidences, significant percentage of
patients have their procedure denied either by risk
considered unacceptable or technical conditions that make
prohibitive the thoracic access, installation of CPB or aortic
clamping. Among them the presence of aortas with
calcifications extensive or in porcelain, presence of pervious
coronary grafts, thoracic radiotherapy or existence of
multiple comorbidities [8]. This population of carriers of
aortic stenosis is not candidate to conventional procedure
and therefore not included in most studies of operative risk
which makes its evaluation doubtful.
Operative risk assessment based in risk scores has
several limitations like non inclusion of some characteristics
deemed as of risk: mediastinal irradiation, aortic porcelain,
hepatic dysfunction, thoracic wall abnormalities and prior
mediastinitis. One should regardless that individuals who
served of basis for composition of scores were patients
who effectively underwent surgery, limiting the inference
in groups originally not considered candidates for
interventional procedure [21].
Within this context, the possibility of less invasive
intervention with the transcatheter aortic valve implant,
both femoral or apical via, has become an attractive
alternative. Several centers have published encouraging
results, however, the mortality still remains significant,
despite the seriousness of the patients and the
advancement of the devices [14.18 ].
The population selected for initial evaluation of this
novel device comprised individuals with risk score extremely
high reaching a Logistic EuroScore of 90.3% and a STS
score of 62.9%, with averages that outweigh most studies
in the literature [22]. Although some cases present risk score
below forecast inclusion criteria these patients were carriers
of comorbidities not contemplated in such criteria and
undescribed previously in individuals undergoing
transcatheter treatment, such as Chagas disease and SCD.
Multiprofessional evaluation justified its selection. Age was
another factor of questioning showing that not only elderly
individuals are candidates to the procedure.
Inclusion of young patient can arouse possibility of
transcatheter intervention as bridge to stabilization until
definitive therapy or even until as destination therapy.
Frequency of comorbidities as aorta porcelain,
peripheral artery disease, coronary artery disease, previous
surgery and renal dysfunction present in population of this
study is higher than in SOURCE registry with consequent
risk elevation [23].
The strategy of implante selected was via transapical
for allowing compatibilization with introducers of larger
caliber and decrease possiblity of peripheral vascular
complications. Several studies have reported increased
mortality with the transapical approach compared to the
transfemoral, but mostly transapical access is reserved for
Fig. 5 – Left ventricular ejection fraction in the pre-,1st, 7th, 30th,
180th, 360th postoperatively.
Preoperative versus 1st postoperative day – P>0,05
Preoperative versus 7th postoperative day – P=0,01
Preoperative versus 30th postoperative– P<0,0001
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cases of failure in the femoral access, which makes the
groups not comparable [23]. On the other hand, the
transapical approach is the access of choice in some groups,
to avoid excessive manipulation of the iliac femoral system
and aortic arch, reducing vascular complications and stroke,
factors known to be implicated in mortality [24].
Hospital mortality of the procedure is quite inconstant
in the literature, but groups mostly are not comparable.
The observed risk is smaller than predicted by risk scores
despite several questionings about validity [22]. Another
important point refers to fact that outcome mortality in 30
days may not explicit actual outcome of the patient since,
as in our sample, many patients can survive initial procedure
and perish after first months due to diverse complications,
especially infectious of high mortality in this fragile group.
Thus outcome of general mortality and its separation by
mortality after discharged is fundamental for correct safety
assessment and procedural efficacy.
Mortality found in 30 days is significant but similar to
literature (18.18%) even considering greater gravity o four
group [22]. And the global mortality (42.42%) is influenced
negatively by infectious complications in the postoperative.
In this sample 39.39% patients were operated under
decompensation and hospitalized, arousing greater risk of
infectious colonization. Conversely, survival after
discharged is quite favorable (90.7%) demonstrating than
that after initial phase the result is sustained and
improvements in postoperative care as implementing of
multiprofessional care are fundamental for success the  of
procedure [12].
The fact that the global mortality observed is similar to
predicted EuroScore (39.30% versus 42.42%) should not
mean that implantation of transcatheter aortic valve has
similar result compared to conventional procedure since
these scores were not calibrated for this population of
patients. Patients selected for this study had their indication
for conventional surgery denied for at least two surgeons.
In groups like these the survival is unfavorable reaching in
1, 2 and 3 years only 50% 25% and 10% respectively [25].
Ye et al. [26] demonstrated in a 3-year follow-up, overall
mortality rate of 42.25%, a result quite similar to that
observed in our sample, and the 30-day mortality of 16.9%,
despite the risk profile is more favorable with lower
EuroSCORE and STS score.
The Partner Trial, recently published, demonstrated
mortality and compound outcomes significantly lower in
group undergone transcatheter therapy compared to clinical
treatment in randomized samples with survival of 1 year of
69.3% for transcatheter group versus 49.3% with clinical
treatment [14], a value similar to found in our sample
(survival 1 years 61.5%).
Minors complications are event of relative frequency
and affect negatively evolution, especially vascular
complications [23]. In the group studied there was only
one vascular complication (without mortality) which added
to insufficient sample size it does not allow conclusions
about impact of this complication in global mortality.
Failure in proper occlusion of the left ventricular apex is
also reported in the literature, being potentially the cause
of two cases of hemothorax requiring reintervention in first
half of the casuistry. Reducing caliber of the introducer of
26Fr to 22Fr  facilitated apical closing and there were no
new cases of bleeding. Conversely, even with introducers
of small caliber the apical occlusion can become challenging
with great blood loss. The possibility of aid of CPB or rescue
blood bsystems can be crucial in patient outcome.
There were two cases of need for renal replacement
with hemodialysis therapy, although 78.78% of the patients
had glomerular filtration rate below 50%. Possibly low use
of iodized contrast collaborated in preservation of renal
function (unused in 60.60% patients).
Structural valvar deterioration is still one parameter of
difficult evaluation and comparison in the literature, given
the small period of follow-up as well as small diversity of
prostheses available. It is worrying the fact that valvar
leaflets need compression and balloon expansion can
theoretically cause their early structural deterioration. In
our study it was not observed deterioration of valvar
function in the leaflets during follow-up but one patient
required new episode of ballooning due to aortic
periprosthetic insufficiency with total resolution.
Atrioventricular block is a complication often described,
reaching a third of patients, especially with the CoreValve
[27]. Balloon expandable prostheses, such as Edwards
Sapiens and Braile, present indices of need for permanent
cardiac stimulation around 4.5% [14]. Only two cases need
definitive pacemaker implantation being only one total
atrioventricular block. Again, little power sample does not
allow to estimate real incidence of disorder with this new
prosthesis.
The need for conversion to the conventional approach,
total cardiopulmonary support and valve replacement is
reported as being around 3.5% [22]. In our sample, there
were two (6.06%) conversions, and one patient died after
30 days due to bronchopneumonia and one is still alive
without complications. Both causes of conversion were
related to the learning curve, with migration of the valve
during implantation. Problems related to valve embolization
occur around 0.5% in trained staff [22]. Among the causative
factors include incorrect assessment of the native valve
(little calcification, asymmetric presence of calcium,
imprecision of measurement of the annulus). The valve
position during the release of the prosthesis is also a
complicating factor, which may cause interference with
mitral apparatus or obstruction of the coronary ostia, this
complication is not present in this sample.
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